Cryo-Cell International, Inc. income statement CCEL

Annual Quarterly

In Q3 of fiscal 2026, the quarter ended Aug 31, 2026, Cryo-Cell International, Inc. reported revenue of $7.8 million, about flat from the same quarter a year earlier. Net income was $1.3 million, a profit margin of 16.2%. Operating income came to $2.2 million, an operating margin of 28.0%. Diluted earnings per share were $0.16.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Aug 31, 2026	Q3 FY2026 Aug 31, 2026	Q2 FY2026 May 31, 2026	Q1 FY2026 Feb 28, 2026	Q4 FY2025 Nov 30, 2025	Q3 FY2025 Aug 31, 2025	Q2 FY2025 May 31, 2025	Q1 FY2025 Feb 28, 2025	Q4 FY2024 Nov 30, 2024
Revenue	31 -2.0%	8 -0.0%	8 -1.9%	8 -3.6%	8 -2.3%	8 -3.0%	8 -1.4%	8 +1.5%	8 +1.9%
Cost of revenue	7 -8.2%	2 -10.4%	2 -9.7%	2 -16.5%	2 +6.0%	2 -15.3%	2 -8.3%	2 -4.0%	2 -19.1%
Gross profit	24 -0.1%	6 +3.1%	6 +0.4%	6 +0.7%	6 -4.4%	6 +1.4%	6 +0.9%	6 +3.4%	6 +9.1%
Research and development	0 -49.0%	0 -13.0%	0 -24.2%	0 -33.0%	0 -72.2%	0 -68.2%	0 -45.4%	0 -80.5%	0 -31.4%
Selling, general and administrative	19 +0.4%	4 -2.5%	5 +8.5%	5 +8.1%	5 -9.3%	4 -6.9%	4 +6.0%	5 +4.7%	6 +10.4%
Operating income	0 -95.6%	2 +15.4%	1 -19.8%	1 -27.5%	-4 -3142.2%	2 +36.7%	1 +7.3%	1 +28.6%	-0 +99.2%
Other non-operating income (expense)	0 -31.5%	0 -98.5%	0 -97.4%	0 +105.0%	0 +240.9%	0 +1690.5%	0 +9335.8%	0 +6360.3%	0 +107940.0%
Other income (expense)	-2 +27.0%	-0 +48.5%	-0 +59.7%	-1 -33.0%	-1 +7.6%	-1 -7027.6%	-1 -1237.5%	-1 -1855.2%	-1 -493.3%
Pretax income	-2 -231.4%	2 +53.9%	1 +43.9%	0 -86.8%	-5 -449.8%	1 -14.0%	1 -60.9%	1 -32.8%	-1 +94.7%
Income tax	0 -98.1%	1 +27.1%	0 +24.6%	0 -90.8%	-1 -179.9%	0 +33.0%	0 -73.1%	0 +5.3%	1 +121.2%
Net income	-2 -310.8%	1 +69.5%	1 +55.9%	0 -83.3%	-4 -105.1%	1 -28.7%	0 -45.7%	0 -49.1%	-2 +83.4%
Basic EPS	-0.24 -311.5%	0.16 +77.8%	0.07 +75.0%	0.01 -66.7%	-0.47 -105.3%	0.09 -30.8%	0.04 -50.0%	0.03 -57.1%	-0.23 +82.9%
Diluted EPS	-0.24 -316.4%	0.16 +77.8%	0.07 +75.0%	0.01 -66.7%	-0.48 -111.0%	0.09 -30.8%	0.04 -50.0%	0.03 -57.1%	-0.23 +83.1%
Weighted average shares, basic	8 -0.2%	8 +0.1%	8 -0.3%	8 -0.3%	8 -0.1%	8 -0.1%	8 -0.5%	8 -2.4%	8 -2.7%
Weighted average shares, diluted	8 -1.3%	8 -0.1%	8 -0.9%	8 -1.8%	8 -2.8%	8 -1.2%	8 -1.3%	8 -1.5%	8 -1.4%
Other measures
Depreciation and amortization	1 -2.0%	0 -1.5%	0 -2.6%	0 -1.5%	0 -2.4%	0 -1.0%	0 +122.9%	0 +188.2%	0 -25.9%
EBITDA	1 -78.2%	2 +13.5%	1 -17.3%	1 -22.6%	-4 -3040.2%	2 +31.1%	2 +15.9%	1 +43.7%	0 +100.8%
Interest coverage	0.10x	5.01x	2.71x	1.65x	-8.23x	3.53x	2.71x	2.13x	-0.16x
Margins
Gross margin	78.54%	79.38%	78.44%	78.44%	77.89%	76.98%	76.58%	75.10%	79.60%
Operating margin	0.61%	28.04%	15.40%	9.96%	-50.58%	24.29%	18.83%	13.25%	-1.52%
Pretax margin	-6.13%	23.33%	10.65%	0.92%	-59.06%	15.16%	7.25%	6.70%	-10.50%
Profit margin	-6.25%	16.24%	7.13%	0.61%	-48.67%	9.58%	4.49%	3.55%	-23.20%
EBITDA margin	3.73%	31.11%	18.53%	13.14%	-47.48%	27.41%	21.98%	16.36%	1.58%
Effective tax rate	—	30.40%	33.00%	33.00%	—	36.81%	38.14%	47.00%	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Services-Misc Health & Allied Services, NEC (SIC 8090)
Listed as: CCEL (NYSE)
Fiscal year ends: November 30
Incorporated in: DE
Headquarters: Oldsmar, FL
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 862692
Former names: CRYO CELL INTERNATIONAL INC (until Oct 28, 2026)

Other Services-Misc Health & Allied Services, NEC companies

All 15 Services-Misc Health & Allied Services, NEC companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.